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Abstract
Background: Shared genetic influences between attention-deficit/hyperactivity disorder (ADHD) symptoms and
autism spectrum disorder (ASD) symptoms have been reported. Cross-trait genetic relationships are, however,
subject to dynamic changes during development. We investigated the continuity of genetic overlap between ASD
and ADHD symptoms in a general population sample during childhood and adolescence. We also studied uni- and
cross-dimensional trait-disorder links with respect to genetic ADHD and ASD risk.
Methods: Social-communication difficulties (N ≤ 5551, Social and Communication Disorders Checklist, SCDC) and
combined hyperactive-impulsive/inattentive ADHD symptoms (N ≤ 5678, Strengths and Difficulties Questionnaire,
SDQ-ADHD) were repeatedly measured in a UK birth cohort (ALSPAC, age 7 to 17 years). Genome-wide summary
statistics on clinical ASD (5305 cases; 5305 pseudo-controls) and ADHD (4163 cases; 12,040 controls/pseudo-controls)
were available from the Psychiatric Genomics Consortium. Genetic trait variances and genetic overlap between
phenotypes were estimated using genome-wide data.
Results: In the general population, genetic influences for SCDC and SDQ-ADHD scores were shared throughout
development. Genetic correlations across traits reached a similar strength and magnitude (cross-trait rg ≤ 1,
pmin = 3 × 10
−4) as those between repeated measures of the same trait (within-trait rg ≤ 0.94, pmin = 7 × 10−4).
Shared genetic influences between traits, especially during later adolescence, may implicate variants in K-RAS signalling
upregulated genes (p-meta = 6.4 × 10−4).
Uni-dimensionally, each population-based trait mapped to the expected behavioural continuum: risk-increasing alleles
for clinical ADHD were persistently associated with SDQ-ADHD scores throughout development (marginal regression
R2 = 0.084%). An age-specific genetic overlap between clinical ASD and social-communication difficulties during
childhood was also shown, as per previous reports. Cross-dimensionally, however, neither SCDC nor SDQ-ADHD scores
were linked to genetic risk for disorder.
Conclusions: In the general population, genetic aetiologies between social-communication difficulties and ADHD
symptoms are shared throughout child and adolescent development and may implicate similar biological pathways
that co-vary during development. Within both the ASD and the ADHD dimension, population-based traits are also linked
to clinical disorder, although much larger clinical discovery samples are required to reliably detect cross-dimensional
trait-disorder relationships.
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Background
An aetiological link between attention-deficit/hyperactivity
disorder (ADHD) symptoms and autism spectrum disorder
(ASD) symptoms has been supported by family [1, 2] and
twin studies [3–7], and shared genetic influences [8, 9]
have been reported both throughout population variation
[3–7, 10] and at the extreme [5, 11]. Clinical ADHD is a
common childhood disorder with a prevalence around
3.4% [12] and characterised by hyperactive-impulsive and
inattentive behavioural symptoms. According to clinical
classification systems, the age of onset for ADHD has been
defined before 7 years [13] and recently changed to 12 years
in DSM-5 [14]. ASD has a typical age of onset before the
age of 3 years [13], affecting ~1 to 2% of children [15, 16].
Core features include deficits in social interaction and
communication, as well as highly restricted interests and/
or stereotyped repetitive behaviours [13]. The underlying
genetic aetiology of both ADHD and ASD is complex, with
contributions of both rare and common variation [17–20]
(where the latter are defined throughout this paper as vari-
ants with a minor allele frequency of ≥1%).
Although twin and family studies suggest that ADHD
and ASD symptoms are co-heritable [8, 9], studies inves-
tigating molecular genetic links between clinical ADHD
and clinical ASD have provided mixed support for the
hypothesis of shared aetiologies between both condi-
tions. Copy number variation (CNV) analyses have iden-
tified shared biological pathways in clinical ADHD and
ASD [21]. Analyses using genome-wide array data [22, 23]
have reported, in contrast, little evidence for genetic over-
lap between both conditions, probably as a consequence of
limited power to date.
Beyond the concept of dichotomous entities, common
disorders such as clinical ASD and ADHD can be under-
stood as extreme values on one or more continuous
underlying scales of liability [24], due to their polygenic
architecture. These views are consistent with theories
conceptualising ADHD and ASD as upper extremes of
an underlying behavioural continuum [25–27], implicat-
ing a uni-dimensional trait-disorder overlap. Studies of
social-communication difficulties assessed in children
from the general population and samples of clinical ASD
have recently identified shared genetic links using
genome-wide summary data [28]. Similarly, population-
based ADHD symptoms, when measured during child-
hood, share genetic links with clinically diagnosed
ADHD, as captured by common polygenic risk [29, 30].
Thus, it is conceivable to ask whether there exist similar
pleiotropic effects between traits and clinical disorders
across behavioural dimensions, implicating links between
ADHD symptoms and clinical ASD and, equivalently,
between ASD symptoms and clinical ADHD, i.e. a cross-
dimensional trait-disorder overlap. However, studies have
demonstrated developmental heterogeneity in the genetic
overlap between ASD and ADHD symptoms, especially in
non-clinical populations [31]. Twin studies reported low
genetic correlations during infancy [32] that rise to mode-
rate strength during childhood and adolescence [31] and
remain moderate to strong in adults [3, 6]. These findings
concur with studies reporting developmental changes
within the genetic architecture of both, ASD and ADHD
symptoms [31]. The contribution of genetic factors to
ASD and ADHD symptom overlap during development,
as tagged by common genetic variation, is, however,
largely unexplored. Recent research started investigating
the association between risk-increasing alleles for clinical
ADHD and communication problems in children from
the general population [29]. Comparatively, little is
known, however, of cross-trait genetic relationships
during child and adolescent development and whether
cross-dimensional trait-disorder relationships are devel-
opmentally sensitive with respect to the age of the
population-based trait.
The aim of this work is to provide insight into the gen-
etic overlap across ADHD- and ASD-related dimensions
during the course of child and adolescent development.
For this, we investigate a phenotypically rich longitudinal
population-based cohort from the UK, the Avon Longitu-
dinal Study of Parents and Children (ALSPAC), as well as
summary statistics from the largest publicly available clini-
cal ADHD and ASD samples collected by the Psychiatric
Genomics Consortium (PGC) [22, 33]. Given the strong
genetic overlap between communication difficulties and
ADHD traits in community twin samples [34], we selected
social-communication difficulties as well as combined
hyperactive-impulsive and inattentive ADHD symptoms
for the study on the population level. Here, we (a) report
and characterise genetic links between longitudinally
assessed social-communication difficulties and combined
hyperactive-impulsive and inattentive ADHD symptoms
within the general population across ages 7 to 17 years,
(b) confirm that these traits genetically overlap with clini-
cal disorder assuming a uni-dimensional behavioural
continuum (unless already reported) and (c) study the
cross-dimensional trait-disorder overlap between these
longitudinally assessed population-based traits with res-
pect to both clinical ADHD and ASD.
Methods
Population-based samples and measures
Population-based analyses were performed in ALSPAC
children, a UK population-based longitudinal pregnancy-
ascertained birth cohort (estimated birth date: 1991 to
1992) [35]. Please note that the study website contains de-
tails of all the data that is available through a fully search-
able data dictionary [36] and that data access can be
requested through the ALSPAC Executive Committee.
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ADHD symptoms
The Strengths and Difficulties Questionnaire (SDQ) [37]
is a behavioural screening instrument with high reliability
and validity with respect to the identification of a psychi-
atric diagnosis [38]. A subscale of the SDQ assesses
combined hyperactive-impulsive and inattentive ADHD
symptoms using five items (three hyperactive-impulsive
and two inattentive items): ‘Restless, overactive. cannot
stay still for long’ (hyperactive-impulsive), ‘Constantly
fidgeting or squirming’ (hyperactive-impulsive), ‘Easily dis-
tracted, concentration wanders’ (inattentive), ‘Thinks
things out before acting’ (hyperactive-impulsive, reverse
coded) and ‘Sees tasks through to the end. Good attention
span’ (inattentive, reverse coded). These items are rated as
‘Not True’ (0), ‘Somewhat true’ (1) and ‘Certainly true’ (2)
and combined into summary score, with higher scores
indicating more behavioural problems (range 0–10).
These items load primarily on their intended factor, i.e.
hyperactivity-impulsivity/inattention, and show min-
imal cross-loadings on other factors assessed by the
SDQ [37, 39]. Mother-reports on their children’s
hyperactivity-impulsivity and inattention were obtained
at 7, 10, 12, 13 and 17 years of age (referred to as SDQ-
ADHD subscale in this study). An additional SDQ-ADHD
measure at 8 years of age was excluded due to potential
bias (Additional file 1: Additional note). Information on
phenotypic and genotypic data was available for 4164 to
5612 children (Table 1, Additional file 1: Table S1).
Social-communication difficulties
Quantitative social-communication difficulties in ALSPAC
participants were measured with the 12-item Social and
Communication Disorders Checklist (SCDC; score range
0 to 24) [40]. The SCDC is a brief screening instrument of
social reciprocity and verbal/nonverbal communication
(e.g. ‘Not aware of other people’s feelings’). It has high
reliability and internal consistency and good discriminant
validity between pervasive developmental disorder and
other clinical groups [40] with higher scores reflecting
more social-communication deficits (positively skewed).
There is substantial trait overlap between the SCDC items
and canonical ASD symptomology, and children with
ASD have high average scores on the SCDC [40]. Mother-
reported SCDC scores for children and adolescents, using
the full scale, were repeatedly measured at 8, 11, 14 and
17 years, and information on phenotypic and genotypic
data was available for 4174 to 5551 children (Table 1,
Additional file 1: Table S1).
Phenotype transformations
Descriptive analyses in R (R.v.3.2.4) showed that untrans-
formed scores for both traits were positively skewed and
predominantly leptokurtic, especially for SCDC scores
(Additional file 1: Table S1), as previously reported [41].
All scores were therefore transformed as some of the
methods used in this study assume multivariate normality
(see below). Specifically, scores were adjusted for sex, age
and the two most significant ancestry-informative princi-
pal components (see below) using ordinary least square
(OLS) regression, and residuals were subsequently
rank-transformed to normality. Within-trait phenotypic
correlations for both, the SDQ-ADHD subscale and the
SCDC, showed phenotypic stability during development,
with stronger correlations across narrower age gaps and
weaker correlations across wider age gaps. Correlation
estimates for both untransformed (based on Spearman’s
Table 1 Population-based and clinical samples
Sample Source Ethnicity Number Phenotype/diagnosis
ALSPACa,b General population White European 5612 (7 y): age(SE) = 6.79(0.11) ADHD symptoms (mother-report)
as assessed with SDQ ADHD scores
5678 (10 y): age(SE) = 9.65(0.12)
5259 (12 y): age(SE) = 11.72(0.13)
5072 (13 y): age(SE) = 13.16(0.18)
4164 (17 y): age(SE) = 16.84(0.18)
ALSPACa,b General population White European 5551 (8 y): age(SE) = 7.65(0.14) Social-communication difficulties
(mother-report) as assessed with
SCDC scores5460 (11 y): age(SE) = 10.72(0.13)
5060 (14 y): age(SE) = 13.90(0.15)
4174 (17 y): age (SE) = 16.84(0.36)
PGC-ADHDc Clinical ADHD sample White European 4163 cases and 12,040 controls/pseudo-controls ADHD or hyperkinetic disorder
PGC-ASDa Clinical ASD sample White European 5305 cases; 5305 pseudo-controls ASD
ADHD attention deficit hyperactivity disorder, ALSPAC Avon Longitudinal study of Parents and Children, ASD autism spectrum disorder, PGC-ADHD ADHD
collection of the Psychiatric Genomics Consortium (PGC), PGC-ASD ASD collection of the PGC, SCDC Social and Communication Disorders Checklist, SDQ-ADHD
ADHD subscale of the Strength and Difficulties Questionnaire, y age in years
aSamples were imputed to a 1000 genomes reference (Phase1_v3)
bALSPAC individuals who were related to participants of the PGC-ADHD sample were excluded
cSamples were imputed to HapMap3 CEU and TSI
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rank correlation) and transformed (based on Pearson
product moment correlation) trait scores were highly
similar (SDQ-ADHD, Additional file 1: Table S2: Spear-
man’s ρ = 0.46 to 0.70; Pearson r = 0.46 to 0.69; SCDC,
Additional file 1: Table S3: Spearman’s ρ = 0.39 to 0.57;
Pearson r = 0.38 to 0.61), as previously reported for the
SCDC [41, 42].
Phenotypic correlations (rp) across traits were esti-
mated using Pearson product moment correlation coeffi-
cients based on rank-transformed traits. To account for
the multiple testing burden within this study, we esti-
mated the effective number of independent population-
based phenotypes studied within this work based on the
eigenvalues of the correlation matrix of the assessed
SCDC and SDQ-ADHD scores [43]. This revealed five
independent measures corresponding to an experiment-
wise error rate of 0.0102. We excluded SCDC scores at
14 years from this calculation, as this measure has very
low single-nucleotide polymorphism heritability (SNP-h2),
as previously reported [42] (shown for completeness only).
The applied experiment-wise error rate is likely to be con-
servative as longitudinal patterns are ignored and mea-
sures with low SNP-h2 will contribute little to genetic
cross-trait links. Therefore, both unadjusted and adjusted
findings are reported.
Genome-wide data
ALSPAC children were genotyped using the Illumina
HumanHap550 quad chip genotyping platforms. The
ALSPAC genome-wide association study (GWAS) data
was generated by Sample Logistics and Genotyping
Facilities at the Wellcome Trust Sanger Institute and
Laboratory Corporation of America using support from
23andMe. After quality control (individual call rate >0.97,
SNP call rate >0.95, Minor allele frequency (MAF) >0.01,
Hardy-Weinberg equilibrium (HWE) p > 10−7 and re-
moval of individuals with cryptic relatedness and non-
European ancestry), 8237 children and 477,482 directly
genotyped SNPs were retained. SNPs were flipped to the
forward strand and haplotypes were estimated with Sha-
peIT (v2.r644) [44]. Pertinent to this study, two ALSPAC
children who were related to participants of the PGC
ADHD sample at the second cousin level (or closer) were
also excluded (based on their genetic relationship). Imput-
ation was performed using Impute V2.2.2 [45] in 1000
genomes reference haplotypes (Phase1_v3 [46]).
Genome-wide summary information on clinical ADHD
The publically available results from an internationally col-
laborative mega-analysis of clinical ADHD, conducted by
the Psychiatric Genomics Consortium (PGC), were utilised
in this study. This sample consisted of 4163 cases and
12,040 controls/pseudo-controls of predominantly Euro-
pean descent [22, 33]. ADHD cases were aged between 5
and 17 years and met diagnostic criteria for either clinical
ADHD or hyperkinetic disorder based on either the Diag-
nostic and Statistical Manual of Mental Disorders (DSM-
III, DSM-IV, DSM-TR) or the International Classification of
Diseases (ICD-10) [33]. Genome-wide data for this mega-
analysis were imputed to a HapMap Phase III European
CEU (HapMap3 CEU) and TSI (HapMap3 TSI) panel.
Genome-wide summary information on clinical ASD
A genome-wide scan of 5305 ASD cases and their par-
ents (PGC-ASD), all of European ancestry (2015 freeze),
has been completed by the PGC. Cases obtained an ASD
diagnosis using research standard diagnoses and expert
clinical consensus diagnoses at the age of 3 years or
above. More than 90% of all patients had also a diagnosis
of autism from the Autism Diagnostic Interview-Revised
[47] and/or the Autism Diagnostic Observation Schedule
[48]. The analyses were conducted using a case and
pseudo-control design [49], which is robust to popula-
tion stratification, as cases and pseudo-controls are
ancestrally matched.
There is no sample overlap between population-based
and clinical samples (Table 1).
Genetic-relationship-matrix restricted maximum
likelihood estimation
Longitudinally assessed SCDC scores and SDQ-ADHD
scores were studied using genetic-relationship-matrix re-
stricted maximum likelihood (GREML) to estimate the
proportion of phenotypic variation due to genetic factors
(genetic variance, Varg), as tagged by common SNPs on
a genotyping chip. Analyses were carried out with
Genome-wide Complex Trait Analysis (GCTA) software
[50]. For rank-transformed traits, estimates of Varg are
equivalent to estimates of SNP-h2, as the phenotypic
variance has been standardised to one. Genetic relation-
ship matrices (GRMs) were constructed using directly
genotyped SNPs, excluding individuals with a pairwise
relationship >0.025 [50].
Bivariate GREML [51] was carried out to estimate gen-
etic correlations (rg) that capture the extent to which two
phenotypes share genetic factors (ranging between −1 and
1), as tagged by common variation. In addition, we report
genetic covariances (Covg). These estimates represent, for
rank-transformed traits [52], the part of the phenotypic
correlation that can be explained by genetic factors. Note
that for rank-transformed traits, the genetic covariance is
equivalent to the product of the square root of the herita-
bilities of the two phenotypes and their genetic correlation
[52]. Genetic relationships were analysed between longitu-
dinally assessed measures of the same trait (‘within-trait’,
i.e. for SCDC and SDQ-ADHD scores separately) and
across traits (‘cross-trait’, i.e. between SCDC and SDQ-
ADHD scores). In addition, we estimated the residual
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correlations (re) between measures. Within-trait analyses
for SCDC scores correspond to previously published find-
ings [42] and are reported for comparison only. All ana-
lyses were performed using rank-transformed residuals in
order to adhere to GREML multivariate normality as-
sumptions. Note that bivariate GREML using untrans-
formed scores (adjusted for covariates) resulted in slow or
no convergence.
Pathway analysis
We used the molecular signatures database (MSigDB)
hallmark gene set collection [53] to dissect the genetic
variance of population-based traits that were assessed at
different stages during development (four SCDC score
measures at 8, 11, 14 and 17 years and five SDQ-ADHD
score measures at 7, 10 12, 13 and 17 years). The gene
sets were derived from multiple ‘founder’ MSigDB gene
sets and represent a specific biological state or process
with coherent expression and little redundancy [53].
For each of the 50 biological pathways, we selected gen-
etic variation from each member of the gene set
(±50 kb flanking each gene boundary, hg19, autosomal
genes only) and constructed two sets of GRMs, using
PLINKv1.9 [54] and GCTA software [50]. The first
GRM contained all SNPs within the gene set (set-
GRM), and the second GRM contained the remaining
SNPs (noset-GRM). Using GREML, we compared full
models (set-GRM and noset-GRM) with reduced
models (noset-GRM only) using likelihood ratio tests
(LRTs). For each pathway, the statistical evidence across
both traits (four SCDC scores at 8, 11, 14 and 17 years
and five SDQ-ADHD scores at 7, 10 12, 13 and
17 years) was finally combined using a homogeneity
statistic [55], accounting for the genetic overlap among
measures (Additional file 1: Additional note). All
pathway-specific meta-analysis statistics were corrected
for 50 independent tests using a Bonferroni threshold.
To allow for the possibility that some signals are driven
by the number of SNPs included in the GRM, which is
approximately proportional to gene size, we also carried
out permutation analyses. We randomly generated 200
sets of genes with similar sizes as observed for the se-
lected pathway to create a null distribution of test sta-
tistics, and derived empirical p values. In addition, we
studied the presence of age-specific and trait-specific
changes in explained genetic variance using a random
effects meta-regression approach (R:metafor), account-
ing for two interrelated traits (four SCDC score mea-
sures at 8, 11, 14 and 17 years and five SDQ-ADHD
score measures at 7, 10 12, 13 and 17 years) and assum-
ing multivariate normality. In addition to a random
intercept, the model included fixed effects for age at as-
sessment and fixed effects for trait (SCDC scores coded
as zero and ADHD-SDQ scores coded as one). Beta
coefficients measure here the increase in variance per
one year as well as the difference in explained variance
between the two traits. A variance/covariance matrix
across the nine measures was approximated analogous
to models accounting for correlated phylogenetic his-
tories [56] including the observed phenotypic correl-
ation matrix between the nine measures weighted by
the standard errors of the genetic variance as estimated
by GREML. We also examined the evidence for a fixed
trait × age interaction effect using LRTs.
Polygenic scoring analyses
Polygenic risk scores (PGS) [57, 58] were generated in
ALSPAC using PGC summary statistics. Using a range
of p value thresholds (0.001 < PT ≤ 1), PGS for ASD
(based on PGC-ASD) and ADHD (based on PGC-ADHD)
were constructed in ALSPAC (Table 1) using imputed ge-
notypes (1000 Genomes, PhaseI_v3, INFO >0.8). Auto-
somal PGC-ASD and PGC-ADHD GWAS signals with
MAF of above 0.01 in ALSPAC were clumped (linkage
disequilibrium r2 > 0.25, ±500 kb) according to current
guidelines [59] using PLINK [54] software and exclud-
ing duplicate SNPs. For age-specific analyses, rank-
transformed population-based traits were regressed on
Z-standardised PGS using ordinary least square re-
gression (Rv3.2.2). The proportion of phenotypic vari-
ance explained by each PGS predictor is reported as
adjusted regression R2. Longitudinal analyses were
carried out using a mixed effects regression modelling
framework (R:lme4). Repeatedly measured untrans-
formed SDQ scores were regressed on PGS including
fixed effects for PGS, sex and age at assessment, and
random slopes (for age) and intercepts. Beta coeffi-
cients for PGS quantify here the increase in trait
scores for each increase in one standard deviation of
PGS. Differences in sample dropout across time were
accounted for through bootstrapping, and we gener-
ated parametric 95% bootstrap confidence intervals
(95% CIBootstrap with NBootstrap = 500). In the presence of
association, we estimated the marginal regression R2 [60]
(R:MuMIn, linear mixed effects models only). Repeatedly
measured untransformed SCDC scores were analysed
similarly, but using a mixed Poisson regression framework
and random intercepts only. Beta coefficients for PGS
quantify in this model the increase in natural-log scores
for each increase in one standard deviation of PGS. Statis-
tical significance for all longitudinal analyses was assessed
using likelihood ratio tests. We finally estimated the ex-
pected genetic covariance between trait and disorder using
the Avengeme software [58, 61], based on findings from
polygenic scoring. We assumed for simplicity, 100,000
causal SNPs for each disorder, and a complex architecture
as described in a recent PGC study [22] (PGC-ASD:
Stergiakouli et al. Molecular Autism  (2017) 8:18 Page 5 of 13
prevalence = 0.01, liability-scale SNP-h2 = 0.17; PGC-
ADHD: prevalence = 0.05, liability-scale SNP-h2 = 0.28).
Results
Genetic variance of traits using longitudinally assessed
measures
Within ALSPAC, the strongest evidence for genetic effects
contributing to SDQ-ADHD scores, as captured by com-
mon variants, was identified during late childhood and
early adolescence (age 12: GREML-Varg(SE) = 0.19(0.07),
p = 0.002; age 13: GREML-Varg(SE) = 0.18(0.07), p =
0.003; Fig. 1a, Additional file 1: Table S4). For SCDC
scores, genetic effects were observed during early and
middle childhood as well as later adolescence (age 8:
GREML-Varg(SE) = 0.24(0.07), p = 7.0 × 10
−5; age 11:
GREML-Varg(SE) = 0.16(0.07), p = 0.005; age 17: GREML-
Varg(SE) = 0.45(0.09), p = 3.0 × 10
−9; Fig. 1b, Additional
file 1: Table S5), with a drop during early adolescence
(age 14: GREML-Varg(SE) = 0.08(0.07), p = 0.10), simi-
lar to previously reported findings on the SCDC [41,
42]. For both traits, estimates of heritability were
nearly identical to genetic variance estimates (Add-
itional file 1: Tables S4 and S5). For comparison only,
we also studied untransformed scores, irrespective of
violations of the assumption of normality, and found
similar results, although the observed estimates were
less strong (Additional file 1: Table S4 and S5).
Within-trait genetic overlap using longitudinally assessed
measures
In the ALSPAC sample, we found evidence for genetic
links among repeatedly assessed SDQ-ADHD scores
throughout development, as estimated with bivariate
GREML. The genetic correlation was strongest for mea-
sures assessed at similar developmental stages (Fig. 1c,
Additional file 1: Table S6), especially during childhood
and early adolescence, and the magnitude of the correl-
ation decreased with increasing age gaps. Similar correl-
ation patterns were also observed for SCDC scores
(Fig. 1d, Additional file 1: Table S7), as previously
reported [42] (shown for completeness only).
Cross-trait genetic overlap using longitudinally assessed
measures
Consistent with phenotypic cross-trait correlations
(Fig. 2a, rpheno p < 0.001, Additional file 1: Table S8) in
ALSPAC, reaching moderate strength across similar age
bands, genetic overlap between SDQ-ADHD and SCDC
scores was identified throughout development (Fig. 2b,
Additional file 1: Table S8). Of note, some cross-trait gen-
etic correlations reached a similar magnitude and strength
as correlations between measures of the same trait (e.g.
SCDCage11_SDQ-ADHDage13: GREML-rg(SE) = 1.00(0.26),
p = 3 × 10−4 versus SDQ-ADHD age10_SDQ-ADHDage12:
GREML-rg(SE) = 0.94(0.13), p = 7 × 10
−4). The respective
genetic covariances were nearly identical (SCDCage11_
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Fig. 1 Genetic architecture of SDQ-ADHD and SCDC scores. Genetic-relationship-matrix restricted maximum likelihood (GREML) genetic variance
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SDQ-ADHDage13: GREML-Covg(SE) = 0.17(0.05) versus
SDQ-ADHDage10_SDQ-ADHDage12: GREML-Covg(SE) =
0.17(0.06)). The relative contribution of genetic to pheno-
typic covariance (i.e. the co-heritability [62]) may, however,
differ by trait (co-heritability SCDCage11_SDQ-ADHDage13:
~41% based on rp = 0.41, Additional file 1: Table S8; co-
heritability SDQ-ADHDage10_SDQ-ADHDage12: ~25% based
on rp = 0.67, Additional file 1: Table S2).
Genetic correlations between SDQ-ADHD and SCDC
scores were, however, developmentally sensitive and
dropped for cross-trait genetic links involving SDQ-ADHD
scores during very early adolescence (~12 years of age), des-
pite cross-trait phenotypic correlations (Fig. 2a). Note that
SDQ-ADHD scores at 12 years are heritable (GREML-Varg
(SE) = 0.19(0.07), p = 0.002; Fig. 1a; Additional file 1: Table
S4) and genetically related to SDQ-ADHD measures at
other ages (Fig. 1c, Additional file 1: Table S6).
Given the evidence for persistent genetic cross-trait
links throughout development, we investigated the hy-
pothesis that phenotypic variation in both traits is influ-
enced by similar biological pathways. As multivariate
approaches to annotate the genetic covariance between
phenotypes are currently not available yet, we dissected
the genetic variance of SCDC scores and SDQ-ADHD
scores (four SCDC score measures at 8, 11, 14 and
17 years and five SDQ-ADHD score measures at 7, 10
12, 13 and 17 years) according to MSigDB hallmark gene
sets and then combined the evidence.
Among the 50 analysed gene sets, genetic variation
within V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog (K-RAS) signalling upregulated genes accounted
for genetic variance in both traits (pmeta = 0.000012; pmeta
(pathway-adjusted) = 6.1 × 10−4; including all repeatedly
assessed measures). The largest variance contributions
were found in later adolescence, where K-RAS signalling
upregulated genes explained nearly 3% in phenotypic vari-
ation in SDQ-ADHD scores and over 6% in SCDC scores
(Fig. 3, Additional file 2: Table S9). We did not observe a
similar joint signal using 200 randomly generated gene
sets, with equivalent gene numbers and gene size as
the K-RAS signalling upregulated gene set (empirical
p < 0.005). Using a random effects meta-regression ap-
proach showed that the genetic variance accounted for
by the K-RAS signalling upregulated gene set increases
with progressing age (βAge(SE) = 0.0029(0.0013), p = 0.023),
with little support for trait-specific effects (βTrait(SE) =
−0.013(0.0093), p = 0.16) or trait-specific developmental
changes (βTrait × Age (SE) = -0.001(0.002), p = 0.67). There
was also little evidence for the contribution of other path-
ways to shared phenotypic variation across traits, beyond
chance (Additional file 2: Table S9).
Genetic overlap between population-based traits and
clinical disorder
To estimate the proportion of phenotypic variance in
population-based traits due to risk increasing alleles
contributing to liability for disorder, we also applied
polygenic scoring.
Uni-dimensional trait-disorder overlap: We found evi-
dence for uni-dimensional trait-disorder overlap between
SDQ-ADHD scores and clinical ADHD throughout de-
velopment. Age-specific association at the nominal level
was observed for SDQ-ADHD measures at 7, 10, 13 and
17 years (Additional file 1: Table S10). Longitudinal
modelling of untransformed SDQ-ADHD scores against
polygenic risk scores suggested that the link between
ADHD scores and clinical ADHD is persistent over time
(for example at a PGS threshold PT = 0.5: βADHD-
PGS(95% CIBootstrap) = 0.067 (0.023, 0.11), p = 0.0043) with
little evidence for developmental changes in effect
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Fig. 2 Cross-trait phenotypic (a) and genetic correlations (b) between SDQ-ADHD and SCDC scores during childhood and adolescence. Using the
ALSPAC cohort, cross-trait phenotypic correlations (rp) were estimated using Pearson product moment correlation coefficients (p ≤ 0.001) and cross-
trait genetic correlations (rg) were estimated with bivariate GREML. ALSPAC Avon Longitudinal Study of Parents and Children, GREML genetic-
relationship-matrix restricted maximum likelihood, GREML-rg bivariate genetic correlation, SCDC Social and Communication Disorders Checklist
at 8, 11, 14 and 17 years (rank-transformed), SDQ-ADHD ADHD subscale of the Strength and Difficulties Questionnaire at 7, 10 12, 13 and
17 years (rank-transformed). rg (p values): *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 (uncorrected for multiple testing, experiment-wise error rate p = 0.01)
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(βADHD-PGS × age (95% CIBootstrap) = 0.0008(−0.005;
0.0074); p = 0.80). The marginal adjusted R2 in SDQ-
ADHD scores due to ADHD-PGS at PT = 0.5 was
0.084%, adjusted for age and sex, and the corresponding
genetic covariance was estimated as 0.10 (95% CI 0.03,
0.17) (approximated SE = 0.035 assuming multivariate nor-
mality). An age-specific genetic link between clinical ASD
and SCDC scores at age 8 (but not later during develop-
ment) has been previously reported [28, 41].
Cross-dimensional trait-disorder overlap: We found
little support that alleles more common in ASD cases
than in controls/pseudo-controls are associated with
variation in SDQ-ADHD scores, including both age-
specific (Additional file 1: Table S11) and longitudinal
models (for example at a PGS threshold PT = 0.5: βASD-
PGS(95% CIBootstrap) = −0.0034 (−0.051, 0.046), p = 0.32).
There was also little evidence that alleles more com-
mon in ADHD cases than in controls/pseudo-controls
are robustly related to variation in SCDC scores at 8, 11,
14 or 17 years (Additional file 1: Table S12) when apply-
ing an experiment-wise error rate of 0.01. There was a
trend for association with rank-transformed SCDC
scores at age 14 years (for example at a PGS threshold
of 0.5: βADHD-PGS_age14(SE) = 0.028(0.01), p = 0.049). Lon-
gitudinal analyses of untransformed scores provided,
however, little evidence for a consistent effect (for example
at a PGS threshold PT = 0.5: βADHD-PGS (95% CIBootstrap) =
0.019 (−0.013, 0.05), p = 0.26) or for a change in polygenic
effect over time (βADHD-PGS × age(95% CIBootstrap) = 0.002
(−9 × 10−5, 0.0049, p = 0.10).
A schematic summary of our results, in combination
with previous findings reported by the PGC, is shown in
Fig. 4.
Discussion
Our findings provide strong evidence for shared genetic in-
fluences between population-based social-communication
difficulties and ADHD symptoms during the course of child
and adolescent development, as tagged by common genetic
variants. Furthermore, population-based traits and disor-
ders were genetically linked within the ASD and within the
ADHD dimension, as suggested by this and previous
analyses [41], although there was little support for cross-
dimensional trait-disorder overlap, with respect to genetic
risk for neither clinical ADHD nor clinical ASD.
Our study shows that in the general population, gene-
tic influences between social-communication difficulties
and ADHD symptoms, as tagged by common genetic
markers, are shared across a ~10-year period spanning
childhood and adolescence. These findings are in agree-
ment with twin study findings in childhood [4, 5], ado-
lescence [31] and adulthood [3, 6]. Genetic correlations
across traits reached a similar strength and magnitude
as those shared between repeated measures of the same
trait, with up to 100% shared genetic influences during
late childhood/early adolescence. At this age, genetic co-
variances contributed to more than a third of the ob-
served cross-trait phenotypic correlation. Moreover, in
absolute terms, the genetic contribution to phenotypic
correlation across traits and between measures of the
Fig. 3 Genetic variance in SDQ-ADHD and SCDC scores due to variation within K-RAS signalling upregulated genes. The genetic variance
composition for SCDC and SDQ-ADHD scores in ALSPAC was dissected according to genetic variation within molecular signatures database
(MSigDB) hallmark gene set collections [53]. For each measure, the genetic variance is shown for the pathway of K-RAS signalling upregulated
genes including one standard error (grey bar) and measurement-specific p values (*p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001). Statistical evidence
across measures was combined using a homogeneity statistic [55], accounting for phenotypic overlap among traits. The meta-analysis p value
(meta-p) reflects four SCDC scores (at 8, 11, 14 and 17 years) and five SDQ-ADHD scores (7, 10 12, 13 and 17 years) and is Bonferroni-adjusted
for 50 analysed pathways (pathway-adjusted). ALSPAC Avon Longitudinal Study of Parents and Children, SCDC Social and Communication Disorders
Checklist at 8, 11, 14 and 17 years (rank-transformed), SDQ-ADHD ADHD subscale of the Strength and Difficulties Questionnaire at 7, 10 12, 13 and
17 years (rank-transformed)
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same trait was nearly identical. Thus, our study suggests
that ASD and ADHD dimensions during late childhood
and early adolescence, as measured by SCDC and SDQ
scores, appear to have no clearly defined boundaries at the
level of genetic variation tagged by common SNPs. This
finding is consistent with a peak in ADHD and ASD symp-
tom co-occurrence during adolescence [9]. In addition, our
results on cross-trait overlap within (near) adult popula-
tions extend twin-based findings in adults and suggest that
shared genetic links with ADHD symptoms may involve
not only repetitive autistic symptoms [6] and social impair-
ment [3] but also social-communication difficulties.
Joint genetic influences implicated in both ADHD
symptoms and social-communication difficulties may in-
clude variation within K-RAS upregulated genes [53]
explaining up to 3 and 6% of trait variation, respectively,
especially during later adolescence. The human K-RAS
gene is an isoform of the RAS oncogene-encoding GDP/
GTP-binding proteins acting as intracellular signal trans-
ducers (OMIM 190070), and RAS proteins play a vital
role in human tissue signalling, including proliferation
and differentiation. K-RAS signalling upregulated genes
involve ~200 loci [53], some of which are ASD candidate
genes such as RELN [63] or are implicated in ASD- and
ADHD-related metabotropic glutamate receptor net-
works based on copy number variation (CNV) ana-
lyses, such as GRM3 [64, 65]. A follow-up study
provided, however, little evidence that genetic variation
within the entire network of metabotropic glutamate re-
ceptors [64, 65] (~266 loci) accounts for genetic variance
in both traits (p = 0.25, data not shown). This may refer
to potential differences between traits, disorders and dif-
ferent types of genetic markers. The variance contribu-
tions explained by K-RAS signalling upregulated genes
increased for both, SDQ-ADHD and SCDC scores, dur-
ing development and were largest during later adoles-
cence with age-dependent developmental but no trait-
dependent changes. Thus, our results do not necessarily
imply that developmentally shared genetic influences be-
tween ADHD symptoms and social-communication dif-
ficulties are genetically stable but that aetiological
mechanisms in both traits are developmentally coupled.
Fig. 4 Genetic relationships between ASD and ADHD symptoms in clinical and population-based samples (as tagged by common variation).
Cross-disorder genetic overlap: The Psychiatric Genomics Consortium (PGC) has previously reported [22] genetic correlations (rg) and covariances
(Covg) between PGC-ASD and PGC-ADHD (rg(SE) = −0.13 (0.09), Covg(SE) = −0.026 (0.017), p = 0.13) using genetic-relationship-matrix restricted
maximum likelihood (GREML) analyses that provided little evidence for cross-disorder genetic overlap. Cross-trait genetic overlap: Genetic correlations and
covariances between standardised SCDC (at 8, 11, 14 and 17 years) and SDQ-ADHD scores (at 7, 10, 12, 13 and 17 years) in ALSPAC, as estimated using
bivariate GREML (a), provided evidence for shared genetic links throughout childhood and adolescence (see the ‘Results’ section). Uni-dimensional trait-
disorder genetic overlap: The association between SDQ-ADHD scores in ALSPAC and ADHD-PGS (polygenic risk scores (PGS)) was developmentally stable
across development, as predicted by linear mixed models (b). A marginal estimate of regression R2 and a marginal estimate of the expected genetic
covariance, as estimated with the Avengeme software (c), are shown (see the ‘Results’ section). As previously reported [41], the association
between ASD risk-increasing alleles and SCDC scores in ALSPAC was strongest at age 8 years. Regression R2 estimates at age 8 years are
shown, based on an age-specific analysis using standardised scores and linear regression models (d) [41]. The expected genetic covariance
was estimated with Avengeme software (c) (Covg(95% CI) = 0.072 (0.0082,0.14) (approximated SE = 0.033)). Cross-dimensional trait-disorder
genetic overlap: There was little support for association between ASD-PGS and SDQ-ADHD or association between ADHD-PGS and SCDC scores
in ALSPAC (see the ‘Results’ section, p > experiment-wise error rate p = 0.01). All polygenic scoring analyses are shown for a PGS threshold (PT)
of 0.5. Genetic relationships reaching statistical significance are shown as solid lines and as dashed lines otherwise. Previous reports based on
linkage disequilibrium score genetic correlations [23, 28] are omitted for clarity. ADHD attention deficit hyperactivity disorder, ALSPAC Avon
Longitudinal Study of Parents and Children, ASD autism spectrum disorder, PGC-ADHD ADHD collection of the PGC, PGC-ASD ASD collection of
the PGC, SCDC Social and Communication Disorders Checklist, SDQ-ADHD ADHD subscale of the Strength and Difficulties Questionnaire
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This clearly underlines the need to investigate genetic
trait variances jointly as part of multivariate analysis ap-
proaches, once these methods become computationally
feasible.
Besides developmental continuity in genetic overlap,
we also noted a drop in cross-trait genetic relationships
involving ADHD symptoms at age 12, irrespective of
their genetic variance and their genetic links with
ADHD symptoms earlier and later during development.
This change in cross-trait genetic correlations was not
captured by cross-trait phenotypic correlations, suggest-
ing that phenotypic links may not always represent an
accurate approximation of the underlying genetic archi-
tecture. It has been shown that children with high
ADHD symptoms at age 12 may follow very different
developmental paths [66] including trajectories of per-
sistent, childhood limited or intermediate ADHD prob-
lems that become apparent during the following stages
of development. It is thus possible to hypothesise that
ADHD symptoms measured at age 12 years are genetic-
ally more heterogeneous than scores assessed at younger
or older ages, and this may have relevance for re-
searchers conducting genome-wide analyses of ADHD
behaviour in large samples. Thus, multivariate decompo-
sitions of phenotypic variance are required, which are
computationally not yet feasible, to disentangle the
underlying variance components shared between ADHD
symptoms before and after this age. In addition, we
cannot exclude the presence of gender-specific effects,
although the power [67] to investigate such effects was
too low in our study (the power is 0.16, assuming 2000
same-sex individuals and a heritability of 0.18 as ob-
served for SDQ-ADHD scores at age 13).
Uni-dimensional analyses of trait-disorder overlap,
conducted within this and previous studies [41], identified a
developmentally stable genetic overlap between population-
based ADHD symptoms of the combined hyperactive-
impulsive/inattentive type and clinical ADHD, as well as an
age-specific overlap between social-communication difficul-
ties during childhood and clinical ASD [28, 41]. These
findings advocate that the investigated population-based
traits each represent dimensional phenotypes mapping to
an underlying ADHD and ASD continuum respectively.
However, investigating cross-dimensional links between
traits and disorder, we found neither robust evidence for
shared genetic aetiologies between social-communication
difficulties and clinical ADHD nor between ADHD symp-
toms and clinical ASD. These findings are consistent with
negligible genetic correlations between clinical ASD and
clinical ADHD in the PGC samples [22, 23]. Using PGC-
ASD as a discovery sample and ALSPAC as target (for ex-
ample SDQ-ADHD scores at age 12), the power [58] to
detect cross-dimensional trait-disorder overlap is low
(0.23), assuming a type I error rate of 0.05 and a cross-
dimensional trait-disorder genetic covariance that corre-
sponds to about half of the uni-dimensional one (see
Fig. 4). Similar power estimates (0.21) were also obtained
when using PGC-ADHD as a discovery sample and
ALSPAC as target (for example SCDC scores at age 8).
Lack of evidence for cross-dimensional trait-disorder
overlap is thus partly a consequence of small clinical dis-
covery samples [59], suggesting that much larger clinical
sample sizes are required to reliably detect cross-
dimensional trait-disorder relationships.
The fraction of phenotypic trait variance that can be
accounted for by risk-increasing alleles for disorder is,
nonetheless, small, even for population-based symptoms
that have been mapped to the same behavioural dimension
(<1%). In light of aetiological differences between subclini-
cal variation in population-based symptoms and severe
neurodevelopmental conditions, it is thus likely that a con-
siderable proportion of genetic factors contributing to
shared genetic links between social-communication diffi-
culties and ADHD symptoms on the general population
level will be non-specific to either disorder. It is further-
more conceivable that genetic links between comorbid
ADHD and ASD symptoms are domain dependent. For ex-
ample, inattentive symptoms tend to be more persistent
than hyperactive-impulsive problems, as the latter tend to
resolve with progressing age [68], possibly pointing to dis-
tinct genetic underpinnings [31]. Thus, investigations of
samples with longitudinal information on behavioural sub-
domains may support analyses of comorbid ADHD and
ASD symptoms.
A limitation of our study is that we cannot fully exclude
the possibility of transformation-related bias with respect
to the studied population-based traits. However, genetic
links between ADHD symptoms and clinical ADHD and
between SCDC scores and clinical ASD, as previously re-
ported [41], were confirmed using untransformed data. In
addition, we cannot exclude the possibility that phenotypic
relationships between population-based traits are upward-
biased due to enhanced variance sharing because of
mother-report, although this is unlikely to affect the re-
ported genetic relationships in children. Furthermore, par-
ticipants with behavioural problems are more likely to
discontinue participation in longitudinal studies [69, 70].
Thus, participants with higher scores on the SCDC and/or
the SDQ-ADHD subscale are more likely to drop out com-
pared to participants with lower scores, as both instru-
ments are known to capture also behavioural difficulties
[37, 40]. Longitudinal analyses of trait-disorder overlap ac-
counting for unequal sample dropout through bootstrap-
ping identified, however, little evidence for bias. Note that
there is also little evidence for sex-specific attrition in
ALSPAC [69]. Finally, our findings of stability and change
in cross-trait genetic relationships during development are
representative of an entire cohort. Thus, our results do not
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allow inferences on participants with extreme behavioural
scores during development, who represent only a small
proportion of the ALSPAC children studied (≤10%) [66].
Conclusions
In the general population, genetic aetiologies between
social-communication difficulties and ADHD symptoms
are linked throughout childhood and adolescence and
may implicate similar biological pathways that are devel-
opmentally coupled. Risk-increasing alleles for disorder
can account, however, only for a very small proportion
of trait variance, even for symptoms mapping to the
same behavioural dimension, suggesting that much lar-
ger clinical samples are required to reliably detect cross-
dimensional trait-disorder relationships.
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